Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 17/20 | 0.54 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA5A | P35218 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16737 | 1.00 | HSD11B1 (0.54) | HSD11B1NR1H3CA1CA2CA5A | |
| SCHEMBL19219 | 1.00 | HSD11B1 (0.54) | HSD11B1NR1H3CA1CA2CA5A | |
| SCHEMBL10165226 | 0.88 | HSD11B1 (0.59) | HSD11B1NR1H3 | |
| SCHEMBL18084415 | 0.86 | HSD11B1 (0.41) | HSD11B1CA1CA2CA5ACA9 | |
| SCHEMBL15459955 | 0.81 | HSD11B1 (0.53) | HSD11B1NR1H3 | |
| SCHEMBL25753451 | 0.81 | HSD11B1 (0.53) | HSD11B1NR1H3 | |
| SCHEMBL18911475 | 0.81 | CYP2A6 (0.40) | HSD11B1CA1CA2CA5ACA9 | |
| SCHEMBL29091902 | 0.81 | CA1 (0.43) | HSD11B1NR1H3CA1CA2CA5A | |
| SCHEMBL28771440 | 0.81 | CA1 (0.43) | HSD11B1NR1H3CA1CA2CA5A | |
| SCHEMBL29091898 | 0.81 | CA1 (0.43) | HSD11B1NR1H3CA1CA2CA5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3210969-B1 | KCNQ2-5 CHANNEL ACTIVATOR | ONO PHARMACEUTICAL CO (JP) | 2021-04-28 | — | — | EP | disclosed |
| CN-107108485-B | KCNQ 2-5 channel activator | 小野药品工业株式会社 | 2020-06-12 | — | — | CN | disclosed |
| US-10676438-B2 | KCNQ2-5 channel activator | ONO PHARMACEUTICAL CO., LTD. (JP) | 2020-06-09 | — | — | US | disclosed |
| US-20200157050-A1 | KCNQ2-5 CHANNEL ACTIVATOR | ONO PHARMACEUTICAL CO., LTD. (JP) | 2020-05-21 | — | — | US | disclosed |
| US-10570093-B2 | — | — | 2020-02-25 | — | — | US | disclosed |
| US-10196358-B2 | KCNQ2-5 channel activator | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-02-05 | — | — | US | disclosed |
| US-20180346422-A1 | KCNQ2-5 CHANNEL ACTIVATOR | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-12-06 | — | — | US | disclosed |
| US-10059705-B2 | Acyclic cyanoethylpyrazolo pyridones as janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-08-28 | — | — | US | disclosed |
| US-9957265-B2 | N-(2-cyano heterocyclyl) pyrazolo pyridones as janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-05-01 | — | — | US | disclosed |
| EP-2976341-B1 | ACYCLIC CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-02-28 | — | — | EP | disclosed |
| US-8431563-B2 | Compounds that interact with glucokinase regulatory protein for the treatment of diabetes | AMGEN INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-8431563-B2 | Compounds that interact with glucokinase regulatory protein for the treatment of diabetes | AMGEN INC. (US) | 2013-04-30 | — | — | US | disclosed |
| WO-2013041042-A1 | PYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-03-28 | — | — | WO | disclosed |
| WO-2013041042-A1 | PYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-03-28 | — | — | WO | disclosed |
| WO-2013040863-A1 | CYCLOALKYLNITRILE PYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-03-28 | — | — | WO | disclosed |
| US-20120225854-A1 | COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-09-06 | — | — | US | disclosed |
| US-20120225854-A1 | COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-09-06 | — | — | US | disclosed |
| US-20120225854-A1 | COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-09-06 | — | — | US | disclosed |
| WO-2012027261-A1 | SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-03-01 | — | — | WO | disclosed |
| WO-2012027261-A1 | SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10570093-B2 | — | KCNQ5, KCNQ2, KCNQ1 | HSD11B1 2566/4885NR1H3 785/4885CA1 2770/4885 |
| US-20200157050-A1 | KCNQ2-5 CHANNEL ACTIVATOR | KCNQ5, KCNQ2, KCNQ1 | HSD11B1 4314/4885NR1H3 1105/4885CA1 3050/4885 |
| US-20120225854-A1 | COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | GCKR, GCK, SLC5A2 | HSD11B1 1443/4885NR1H3 1997/4885CA1 4137/4885 |
| US-10059705-B2 | Acyclic cyanoethylpyrazolo pyridones as janus kinase inhibitors | JAK1, JAK2, JAK3 | HSD11B1 2633/4885NR1H3 2906/4885CA1 3144/4885 |
| US-20180346422-A1 | KCNQ2-5 CHANNEL ACTIVATOR | KCNQ5, KCNQ2, KCNQ1 | HSD11B1 4314/4885NR1H3 1105/4885CA1 3050/4885 |
| US-10676438-B2 | KCNQ2-5 channel activator | KCNQ5, KCNQ2, KCNQ1 | HSD11B1 4314/4885NR1H3 1105/4885CA1 3050/4885 |
| US-10196358-B2 | KCNQ2-5 channel activator | KCNQ5, KCNQ2, KCNQ1 | HSD11B1 4314/4885NR1H3 1105/4885CA1 3050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.